Researchers in Norway have shown the superiority of combined fluciclovine F-18 PET with multiparametric MRI over either modality alone for detecting and characterizing high-risk prostate cancers, according to a study published Oct. 6 in the Journal of Nuclear Medicine.  {read more here}